— Remdesivir analogue demonstrates non-inferiority, good safety in Chinese randomized trial

by Ingrid Hein, published in MedPage Today on January 3, 2023

An oral remdesivir analogue (VV116) was just as good as nirmatrelvir-ritonavir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease, and may be safer, results of a phase III trial from China suggested.

Sustained clinical recovery of COVID-19 symptoms with a 5-day course of VV116 proved noninferior to nirmatrelvir-ritonavir, with patients recovering at a median 4 days versus 5 days, respectively, from the start of treatment (HR 1.17, 95% CI 1.02-1.36), according to Ren Zhao, MD, PhD, of Shanghai Jiao Tong University School of Medicine, and colleagues.

Link to continue reading full article in MedPage Today by Ingrid Hein



Submit a Comment